Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra

Nicole DeFeudis

Editor

Madrigal Pharmaceuticals is “off to a strong start” with its recently approved MASH drug Rezdiffra, CEO Bill Sibold said on Wednesday. The company pulled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra